Skip to main content
. Author manuscript; available in PMC: 2017 Jul 11.
Published in final edited form as: Oncogene. 2017 Feb 20;36(26):3749–3759. doi: 10.1038/onc.2017.1

Figure 5. MIF overexpression in bevacizumab-resistant cells decreases tumor-associated macrophages and drives M1 polarization in vivo.

Figure 5

Intracranial xenografts established from U87-BevR glioma cells transduced to overexpress MIF in two different clones relative to U87-BevR cells transduced with empty vector (EV) exhibited (n=3/group) (a) decreased tumor weight (P=0.03 U87-BevR/MIF1 and P=0.009 U87-BevR/MIF2); (b) increased CD11b+ TAMs (P=0.006 for both U87-BevR/MIF1 and U87-BevR/MIF2 compared to U87-BevR/EV) (CD11b+ cells red, GFP+ tumor cells green, DAPI rendering nuclei blue); (c) increased M1/M2 ratio (P=0.002 U87/BevR-MIF1, P=0.01 U87/BevR-MIF2); and (d) decreased vascularity (P=0.046 U87-BevR/MIF1 and P=0.04 U87-BevR/MIF2). Scale bars, 50 µm.